Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bausch HealthBHC +0.88%58 3-1 Month Momentum % is -17.78% as of Jul. 23, 2026. GuruFocus rates BHC with a GF Score™ of 58/100 and a GF Value™ of $7.92 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,022 Drug Manufacturers companies, Bausch Health ranks worse than 66.83% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-23), Bausch Health's 3-1 Month Momentum % is -17.78%.
The industry rank for Bausch Health's 3-1 Month Momentum % or its related term are showing as below:
BHC's 3-1 Month Momentum % is ranked worse than 66.83% of 1022
companies
in the Drug Manufacturers industry
Industry Median: -9.5
vs BHC: -17.78
Bausch Health (NYSE:BHC) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Bausch Health 3-1 Month Momentum % Related Terms
BHC vs ZTS, UTHR: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Bausch Health's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bausch Health 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bausch Health's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Bausch Health's 3-1 Month Momentum % falls into.
Bausch Health (NYSE:BHC) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bausch Health (BHC) has a 3-1 Month Momentum % of -17.78% as of Jul. 23, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Bausch Health and its competitors. According to the industry distribution chart, Bausch Health ranks #683 out of 1022 companies in the Drug Manufacturers industry, placing it in the top 66.8%.
Is Bausch Health's 3-1 Month Momentum % too high?
Bausch Health's current 3-1 Month Momentum % is -17.78%. Based on the distribution chart, Bausch Health ranks #683 out of 1022 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Bausch Health has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bausch Health's 3-1 Month Momentum % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bausch Health ranks #683 out of 1022 companies for 3-1 Month Momentum %. This places Bausch Health in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Bausch Health and its competitors. Bausch Health's current 3-1 Month Momentum % is -17.78%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch Health stock overvalued right now?
Based on GuruFocus' analysis, Bausch Health (BHC) is currently considered Possible Value Trap. The stock's GF Value™ is $7.92, compared to a current price of $4.56 — trading 42.4% below its estimated fair value. The current 3-1 Month Momentum % is -17.78%. Bausch Health's overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Bausch Health (BHC), the current 3-1 Month Momentum % is -17.78% as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bausch Health (BHC) Overvalued in 2026?
Based on GuruFocus' analysis, Bausch Health stock appears to be undervalued.
The current stock price of $4.56 is trading 42.4% below its estimated GF Value™ of $7.92.
GuruFocus considers Bausch Health to be Possible Value Trap.
Key valuation signals for BHC:
3-1 Month Momentum %: -17.78%
GF Value™: $7.92 vs. price of $4.56 (42.4% below fair value)
No single metric tells the full story. See the BHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
58GF Score
Get the complete analysis for BHC
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BHC has been successfully added to your 
